Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/127
A61P-043/00
A61K-031/7088
C12N-015/88
출원번호
US-0679875
(2008-09-24)
등록번호
US-9498493
(2016-11-22)
국제출원번호
PCT/CA2008/001678
(2008-09-24)
§371/§102 date
20100324
(20100324)
국제공개번호
WO2009/039628
(2009-04-02)
발명자
/ 주소
Mansour, Marc
Karkada, Mohan
Weir, Genevieve Mary
출원인 / 주소
IMMUNOVACCINE TECHNOLOGIES INC.
대리인 / 주소
Husch Blackwell LLP
인용정보
피인용 횟수 :
1인용 특허 :
80
초록
The invention provides compositions comprising a carrier comprising a continuous phase of a hydrophobic substance, liposomes, and a polynucleotide, and methods for using such compositions for delivering a polynucleotide to a subject.
대표청구항▼
1. An injectable composition comprising: a carrier comprising mannide oleate and a continuous phase of mineral oil;liposomes comprising an unsaturated phospholipid; anda polynucleotide encapsulated within said liposomes, said polynucleotide encoding a polypeptide and being operably linked to a promo
1. An injectable composition comprising: a carrier comprising mannide oleate and a continuous phase of mineral oil;liposomes comprising an unsaturated phospholipid; anda polynucleotide encapsulated within said liposomes, said polynucleotide encoding a polypeptide and being operably linked to a promoter functional in mammalian cells; wherein said carrier and said liposomes are present in a ratio of 1:1 by volume. 2. The composition according to claim 1, wherein the composition is a water-in-oil emulsion. 3. The composition according to claim 1, wherein the liposomes comprise cholesterol. 4. The composition of claim 1, wherein the liposomes comprise dioleoyl phosphatidylcholine (DOPC) and cholesterol. 5. The composition according to claim 1, further comprising an adjuvant. 6. The composition according to claim 1, wherein said polynucleotide is inserted in an expression plasmid. 7. The composition according to claim 1, comprising a bacterial or viral vector containing said polynucleotide. 8. The composition according to claim 1, wherein said polynucleotide is present both encapsulated within said liposomes and exterior to said liposomes. 9. The composition according to claim 5, wherein said adjuvant is present: (a) within said liposomes;(b) exterior to said liposomes; or(c) both within said liposomes and exterior to said liposomes. 10. A kit, comprising: a composition of claim 1; and instructions for using said composition to deliver a polynucleotide to a subject. 11. A method for delivering a polynucleotide to a subject, comprising administering the composition of claim 1 to said subject. 12. The method according to claim 11, wherein said subject is a mammal. 13. The method according to claim 12, wherein said mammal is a human. 14. A method for making a composition comprising: (a) providing a polynucleotide that encodes a polypeptide and that is operably linked to a promoter functional in mammalian cells;(b) encapsulating said polynucleotide in liposomes comprising an unsaturated phospholipid; and(c) combining said liposomes with a carrier comprising mannide oleate and a continuous phase of mineral oil in a ratio of 1:1 by volume. 15. The method according to claim 14, wherein the liposomes are dehydrated before they are combined with said carrier. 16. A composition produced by the method according to claim 14. 17. The composition according to claim 1, wherein said polypeptide is an antigen, an antibody or antibody fragment, an enzyme, a cytokine, a therapeutic protein, a chemokine, a regulatory protein, a structural protein, a chimeric protein, a nuclear protein, a transcription factor, a viral protein, a TLR protein, an interferon regulatory factor, an angiostatic or angiogenic protein, an apoptotic protein, an Fc gamma receptor, a hematopoietic protein, a tumor suppressor, a cytokine receptor, or a chemokine receptor. 18. The method according to claim 11, wherein said polypeptide is an antigen, an antibody or antibody fragment, an enzyme, a cytokine, a therapeutic protein, a chemokine, a regulatory protein, a structural protein, a chimeric protein, a nuclear protein, a transcription factor, a viral protein, a TLR protein, an interferon regulatory factor, an angiostatic or angiogenic protein, an apoptotic protein, an Fc gamma receptor, a hematopoietic protein, a tumor suppressor, a cytokine receptor, or a chemokine receptor. 19. The method according to claim 14, wherein said polypeptide is an antigen, an antibody or antibody fragment, an enzyme, a cytokine, a therapeutic protein, a chemokine, a regulatory protein, a structural protein, a chimeric protein, a nuclear protein, a transcription factor, a viral protein, a TLR protein, an interferon regulatory factor, an angiostatic or angiogenic protein, an apoptotic protein, an Fc gamma receptor, a hematopoietic protein, a tumor suppressor, a cytokine receptor, or a chemokine receptor.
Dunbar Bonnie S. (2001 Holcombe #2302 Houston TX 77030) Prasad Sarvamangala V. (5123 Jackwood Houston TX 77096), Contraceptive vaccine comprising a glycosylated 55 kD zona pellucida protein immunogen and method of use of the same in.
Koelle,David M.; Hosken,Nancy A.; Posavad,Christine M.; Chen,Hongbo; McGowan,Patrick, Immunologically significant herpes simplex virus antigens and methods for using same.
Fountain Michael W. (Plainsboro NJ) Weiss Steven J. (Lawrenceville NJ) Kearns John J. (Princeton NJ) Weiner Alan L. (Plainsboro NJ) Popescu Mircea C. (Plainsboro NJ), Lipid matrix carriers for use in drug delivery systems.
Woodle Martin C. (Menlo Park CA) Martin Francis J. (San Francisco CA) Yau-Young Annie (Los Altos CA) Redemann Carl T. (Walnut Creek CA), Liposomes with enhanced circulation time.
Howard Sands ; Awadhesh Mishra CA, Method for administering camptothecins via injection of a pharmaceutical composition comprising microdroplets containing a camptothecin.
Brown Robert,CAX ; Mezei Michael,CAX ; Pohajdak Bill,CAX ; Kimmins Warwick Charles,CAX, Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome a.
Brown Robert,CAX ; Mezei Michael,CAX ; Mezei Catherine,CAX ; Pohajdak Bill,CAX ; Kimmins Warwick Charles,CAX, Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome and adjuvant.
Popescu Mircea C. ; Weiner Alan L. ; Recine Marie S. ; Janoff Andrew S. ; Estis Leonard ; Keyes Lynn D. ; Alving Carl R., Potentiation of immune responses with liposomal adjuvants.
Leveugle, Beatrice; Madiyalakan, Ragupathy; Noujaim, Antoine A.; Schultes, Birgit, Reagents and methods for inducing an immune response to prostate specific antigen.
Mansour, Marc; Karkada, Mohan; Weir, Genevieve Mary, Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.